Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

The American journal of cardiology - 16 Nov 2009

Barter Philip

Abstract excerpt

Inhibition of the cholesteryl ester transfer protein (CETP), a plasma protein that normally transfers cholesterol from the protective high-density lipoprotein (HDL) fraction to the atherogenic low-density lipoprotein (LDL) fraction, results in an increase in the concentration of HDL cholesterol and a decrease in the concentration of LDL cholesterol and has been shown in rabbits to inhibit the development of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol Ester Transfer Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, HDL

Share to Cholesterol, LDL

Share to Coronary Artery Disease

Share to Genetic Predisposition to Disease

Share to Quinolines

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 19895939
DOI: 10.1016/j.amjcard.2009.09.014

Genes

CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.PMID 19895939Read ↗

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.Semantic proximity Read ↗

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.Semantic proximity Read ↗

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.Semantic proximity Read ↗

CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.Semantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular diseaseSemantic proximity Read ↗

Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.Semantic proximity Read ↗

CETP inhibitors and cardiovascular disease: Time to think againSemantic proximity Read ↗

Achieved LDL-C levels <55 mg/dL and cardiac events in patients and lesions harbouring lipid-rich plaque phenotypes.Semantic proximity Read ↗

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial.Semantic proximity Read ↗

Statins and the coronary plaque calcium "paradox": Insights from non-invasive and invasive imaging.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.